Insect poison allergens with reduced IgE reactivity and...

Details Insect poison allergens with reduced IgE reactivity and... Insect poison allergens with reduced IgE reactivity and...

2007-08-09

2011-11-01

Rooney, Nora (Department: 1644)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S275100, C514S001100, C530S350000

Reexamination Certificate

active

08048424

ABSTRACT:
The invention relates to recombinant insect poison allergens and to a specific method for producing them. Said allergens can be varied according to whether they are produced using folds (conformations) that are identical or different to those that occur naturally. The proteins with folds that do not occur naturally have a reduced IgE reactivity or allergenity and can therefore be used as therapeutic agents in the immunotherapy of allergies.

REFERENCES:
patent: 5804201 (1998-09-01), King
Larche et al. ‘Immunological mechanisms of allergen-specific immunotherapy.’ Nat. Rev. Immunol. 6(10):761-771, 2006.
Mukhopadhyay et al. ‘Inclusion bodies and purification of proteins in biologically active forms.’ Adv. Biochem. Eng. 56:61-109, 1997.
Howlett et al. ‘Role of carbohydrates as an antigenic determinant of a glycoprotein from rye-grass (Lolium perenne) pollen.’ Biochem. J. 197:707-714, 1981.
King, et al., “Murine T and B Cell Response to Natural and Recombinant Hornet Venom Allergen Do1 m 5.02 and its Recombinant Fragments”, The Journal of Immunology, vol. 154, pp. 577-584, 1995.
Suck, et al., “Purification and Immunobiological Characterization of Folding Variants of the recombinant Major Wasp Allergen ves v 5 (Antigen 5)”, International Archives of Allergy and Immunology, vol. 121, pp. 284-291, Apr. 2000.
Monsalve, et al., “Expressions of Recombinant Venom Allergen, Antigen 5 of Yellowjacket (Vespula vulgaris) and Paper Wasp (Polistes annularis), in Bacteria and Yeast”, Protein Expression and Purification, vol. 16, pp. 410-416, Aug. 1999.
Forster et al., “Natural and Recombinant Enzymatically Active or Inactive bee venom Phospholipase A2 has the same Potency to Release Histamine from Basophils in Patients with Hymenoptera Allergy”, The Journal of Allergy and Clinical Immunology, vol. 95, pp. 1229-1235, 1995.
Soldatova, et al., “Superior Biologic Activity of the Recombinant bee venom Allergen Hyaluronidase Expressed in Baculovirus-Infected Insect Cells as Compared withEscherichia coli”, The Journal of Allergy and Clinical Immunology, vol. 101, pp. 691-698, 1998.
Fang et al., “cDNA cloning and primary structure of a white-face hornet venom allergen, antigen 5”, Proc. Natl. Acad. Sci. USA, vol. 85, pp. 895-899, Feb. 1988.
King et al., “Hymenoptera Allergens, in Allergens and Allergen Immunotherapy”, third edition, Macel Dekker, Inc. 2004, pp. 339-353.
Rudolph et al., Faseb J, 1996, 10:49-56.
Cabrita et al., Biotechnol Annu Rev. 2004, 10:31-50.
Fischer, BE Bitech Adv, 1994, 12:89-101.

Affiliated with

Also associated with

Rating

Insect poison allergens with reduced IgE reactivity and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Insect poison allergens with reduced IgE reactivity and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Insect poison allergens with reduced IgE reactivity and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4282341